Aiman Shalabi

710 total citations
17 papers, 526 citations indexed

About

Aiman Shalabi is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aiman Shalabi has authored 17 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aiman Shalabi's work include CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Aiman Shalabi is often cited by papers focused on CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Aiman Shalabi collaborates with scholars based in United States, United Kingdom and Canada. Aiman Shalabi's co-authors include Ramy Ibrahim, Ross Stewart, Laura Pearce, Jun Tang, Vanessa M. Hubbard-Lucey, Jill O’Donnell-Tormey, Matthew Boron, Frank M. Balis, Percy Ivy and Diane E. Cole and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature Reviews Drug Discovery.

In The Last Decade

Aiman Shalabi

16 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aiman Shalabi United States 9 273 122 103 88 66 17 526
Olivier Colomban France 13 195 0.7× 32 0.3× 39 0.4× 72 0.8× 50 0.8× 47 501
Pei‐Hung Chang Taiwan 15 380 1.4× 35 0.3× 41 0.4× 172 2.0× 28 0.4× 66 734
Scott A. Soefje United States 8 139 0.5× 53 0.4× 14 0.1× 35 0.4× 39 0.6× 29 369
Giuseppe Scaletta Italy 20 177 0.6× 45 0.4× 59 0.6× 65 0.7× 36 0.5× 46 1.0k
Gholamreza Bahoush Iran 10 52 0.2× 29 0.2× 65 0.6× 37 0.4× 59 0.9× 40 273
Hye Jung Chang South Korea 14 275 1.0× 33 0.3× 62 0.6× 146 1.7× 21 0.3× 26 543
Olumide B. Gbolahan United States 18 312 1.1× 46 0.4× 70 0.7× 179 2.0× 17 0.3× 65 766
Muhammed Bülent Akıncı Türkiye 11 154 0.6× 24 0.2× 19 0.2× 101 1.1× 8 0.1× 49 342
Andrea Corkhill United Kingdom 8 317 1.2× 51 0.4× 31 0.3× 115 1.3× 7 0.1× 12 481
Janelle M. Fauci United States 9 204 0.7× 72 0.6× 54 0.5× 34 0.4× 44 0.7× 19 366

Countries citing papers authored by Aiman Shalabi

Since Specialization
Citations

This map shows the geographic impact of Aiman Shalabi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aiman Shalabi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aiman Shalabi more than expected).

Fields of papers citing papers by Aiman Shalabi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aiman Shalabi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aiman Shalabi. The network helps show where Aiman Shalabi may publish in the future.

Co-authorship network of co-authors of Aiman Shalabi

This figure shows the co-authorship network connecting the top 25 collaborators of Aiman Shalabi. A scholar is included among the top collaborators of Aiman Shalabi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aiman Shalabi. Aiman Shalabi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Britten, Cedrik M., Aiman Shalabi, & Axel Hoos. (2021). Industrializing engineered autologous T cells as medicines for solid tumours. Nature Reviews Drug Discovery. 20(6). 476–488. 15 indexed citations
2.
D’Angelo, Sandra P., Jonathan Noujaim, Fiona Thistlethwaite, et al.. (2021). IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).. Journal of Clinical Oncology. 39(15_suppl). TPS11582–TPS11582. 8 indexed citations
3.
4.
Schoenfeld, Adam J., Mehmet Altan, Taofeek K. Owonikoko, et al.. (2021). Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).. Journal of Clinical Oncology. 39(15_suppl). TPS2661–TPS2661. 1 indexed citations
5.
6.
Pankov, Dmitry, Ioanna Eleftheriadou, Sara Brett, et al.. (2020). 96 Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo. SHILAP Revista de lepidopterología. A60.2–A61. 1 indexed citations
7.
Eleftheriadou, Ioanna, Sara Brett, Magdalena Kijewska, et al.. (2019). NY-ESO-1 and LAGE1A: An emerging target for cell therapies in solid tumours. Annals of Oncology. 30. v503–v503. 2 indexed citations
8.
Maio, Michele, George Coukos, Soldano Ferrone, et al.. (2018). Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy. Cancer Immunology Immunotherapy. 68(1). 1–9. 8 indexed citations
9.
Tang, Jun, Vanessa M. Hubbard-Lucey, Laura Pearce, Jill O’Donnell-Tormey, & Aiman Shalabi. (2018). The global landscape of cancer cell therapy. Nature Reviews Drug Discovery. 17(7). 465–466. 61 indexed citations
10.
Ibrahim, Ramy, Ross Stewart, & Aiman Shalabi. (2015). PD-L1 Blockade for Cancer Treatment: MEDI4736. Seminars in Oncology. 42(3). 474–483. 76 indexed citations
11.
Fairman, David, Rajesh Narwal, Meina Liang, et al.. (2014). Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2602–2602. 21 indexed citations
12.
Lutzky, Jose, Scott Antonia, Andy Blake-Haskins, et al.. (2014). A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 3001–3001. 85 indexed citations
13.
Krug, Lee M., Alessandra di Pietro, Rajesh Narwal, et al.. (2013). A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma. Journal for ImmunoTherapy of Cancer. 1(S1). 3 indexed citations
14.
Widemann, Brigitte C., Frank M. Balis, AeRang Kim, et al.. (2010). Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome. Journal of Clinical Oncology. 28(25). 3979–3986. 106 indexed citations
15.
Balis, Frank M., Matthew Boron, Aiman Shalabi, et al.. (2005). Carboxypeptidase-G2 (CPDG2) and leucovorin (LV) rescue with and without addition of thymidine (Thd) for high-dose methotrexate (HDMTX) induced renal dysfunction. Journal of Clinical Oncology. 23(16_suppl). 2076–2076. 2 indexed citations
16.
Widemann, Brigitte C., Frank M. Balis, Aiman Shalabi, et al.. (2004). Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2. JNCI Journal of the National Cancer Institute. 96(20). 1557–1559. 39 indexed citations
17.
Köhler, David, Michael Montello, Barry R. Goldspiel, et al.. (2002). ASHP Guidelines on Preventing Medication Errors with Antineoplastic Agents. American Journal of Health-System Pharmacy. 59(17). 1648–1668. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olivier Colomban Breakdown of academic impact, for papers by Pei‐Hung Chang Breakdown of academic impact, for papers by Scott A. Soefje Breakdown of academic impact, for papers by Giuseppe Scaletta Breakdown of academic impact, for papers by Gholamreza Bahoush Breakdown of academic impact, for papers by Hye Jung Chang Breakdown of academic impact, for papers by Olumide B. Gbolahan Breakdown of academic impact, for papers by Muhammed Bülent Akıncı Breakdown of academic impact, for papers by Andrea Corkhill Breakdown of academic impact, for papers by Janelle M. Fauci
Rankless by CCL
2026